StockData

CG Oncology vs Caribou Biosciences

CGON and CRBU side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CGON and CRBU compare

CG Oncology is the larger company, worth 199 times as much as Caribou Biosciences ($7.5B against $37.8M).

CG Oncology grew revenue faster over the last twelve months (184% versus 10.0% for Caribou Biosciences).

Caribou Biosciences keeps more of each dollar of sales as profit, with a net margin of −1030% compared with −3851% at CG Oncology.

Caribou Biosciences scores higher on the StockData Score (9 against 5 for CG Oncology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCGONCRBU
Size and price
Market cap$7.5B$37.8M
Share price$84.78$0.353
Change, 1 year125%−82.2%
Change, 5 years–−98.0%
Beta (5Y)0.241.36
Employees14297
StockData Score
Total score59 (better)
Valuation score03 (better)
Growth score11
Performance score1 (better)0
Health score35 (better)
Dividend score00
Valuation
P/S1219×3.8× (better)
P/B7.6×0.4× (better)
FCF yield−2.5% (better)−253%
Fair value–$1.29
Margin of safety–72.6%
Growth
Revenue growth (TTM)184% (better)10.0%
Revenue growth, 5Y average–−2.0%
Profitability
Operating margin−4294%−1091% (better)
Net margin−3851%−1030% (better)
FCF margin−3068%−954% (better)
Return on equity−28.3% (better)−78.3%
Return on invested capital−2103%–
Financial health
Debt / equity0.00 (better)0.00
Current ratio21.70 (better)6.49
Altman Z-score80.45 (better)−7.46
Piotroski F-score12 (better)
Dividends and buybacks
Buyback yield−6.5% (better)−64.0%
Shareholder yield−6.5% (better)−64.0%
Ownership
Held by institutions106%45.5%
Held by insiders17.3%5.7%
Insider net buying, 12 months$20.0M (better)−$47.5K
Short interest, % of float12.6%14.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.